Aumilto Silva, Medical Oncologist and Clinical Research at Hospital Santa Catarina Paulista, shared a post on X:
“In an indirect comparison of phase III trials (EMBER-3, MONARCH 2, postMONARCH), imlunestrant + abemaciclib showed a consistent numerical PFS advantage vs fulvestrant + abemaciclib (HR ~0.77–0.83), despite no head-to-head trial.
Beyond efficacy, this study highlights a key paradigm shift:
- Oral SERDs overcome limitations of fulvestrant (IM delivery, suboptimal exposure)
- Enable fully oral, targeted combinations
- Potentially improve adherence, tolerability, and patient experience
While hypothesis-generating, this analysis supports oral SERDs as a rational and potentially more effective partner to CDK4/6 inhibition, strengthening their role as the future endocrine backbone in HR+/HER2– advanced disease.”
Title: Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials
Authors: K. Jhaveri, F. C. Bidard, K. Kalinsky, P. Neven, H. S. Rugo, S. M. Tolaney, L. M. Litchfield, C. C. von Laue, S. Traore, F. Sapunar, Y. Li and J. O’Shaughnessy
Other articles featuring Aumilto Silva on OncoDaily.
